This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Oral hypertensive treatments

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

oral antihypertensive agents

Primary agents

  • thiazide or thiazide-type diuretics
    • e.g - Chlorthalidone, Hydrochlorothiazide, Indapamide, Metolazone
    • Cchlorthalidone preferred based on prolonged half-life and proven trial reduction of CVD
    • monitor for hyponatremia and hypokalemia, uric acid and calcium levels
    • use with caution in patients with history of acute gout unless patient is on uric acid-lowering therapy

  • ACE Inhibitors
    • e.g. ramipril
    • do not use in combination with ARBs or direct renin inhibitor
    • increased risk of hyperkalemia, especially in patients with CKD or in those on K+ supplements or K+-sparing drugs
    • may cause acute renal failure in patients with severe bilateral renal artery stenosis
    • do not use if history of angioedema with ACE inhibitors
    • avoid in pregnancy

  • ARBs
    • e.g. candesartan, losartan
    • do not use in combination with ACE inhibitors or direct renin inhibitor
    • increased risk of hyperkalemia in CKD or in those on K+ supplements or K+-sparing drugs
    • may cause acute renal failure in patients with severe bilateral renal artery stenosis
    • do not use if history of angioedema with ARBs. Patients with a history of angioedema with an ACEI can receive an ARB beginning 6 weeks after ACEI discontinued
    • avoid in pregnancy

  • calcium channel blockers (CCB) - dihydropyridines
    • e.g. - Amlodipine, Felodipine
    • avoid use in patients with , heart failure with reduced ejection fraction (HFrEF); amlodipine or felodipine may be used if required
    • associated with dose-related pedal edema, which is more common in women than men

  • CCB - nondihydropyridines
    • e.g. - Diltiazem, Verapamil
    • avoid routine use with beta blockers due to increased risk of bradycardia and heart block
    • do not use in patients with HFrEF

Secondary agents

  • diuretic-loop
    • e.g. - Bumetanide, Furosemide
    • these are preferred diuretics in patients with symptomatic HF. They are preferred over thiazides in patients with moderate-to-severe CKD (e.g., GFR<30ml/min)
  • diuretic-potassium sparing
    • e.g. - Amiloride
    • these are monotherapy agents and minimally effective antihypertensive agents.
    • combination therapy of potassium-sparing diuretic with a thiazide can be considered in patients with hypokalemia on thiazide monotherapy
    • avoid in patients with significant CKD (e.g., GFR<45ml/min)

  • diuretic- aldosterone antagonists
    • e.g. - Eplerenone, Spironolactone
    • preferred agents in primary aldosteronism and resistant hypertension
    • spironolactone associated with greater risk of gynecomastia and impotence compared to eplerenone
    • common add-on therapy in resistant hypertension
    • avoid use with K+ supplements, other K+-sparing diuretics or significant renal dysfunction
    • Eplerenone often requires twice daily dosing for adequate BP lowering

  • beta blocker- cardioselective
    • e.g. - Atenolol, Bisoprolol
    • beta blockers are not recommended as first-line agents unless the patient has IHD or HF.
    • these are preferred in patients with bronchospastic airway disease requiring a beta blocker
    • Bisoprolol and metoprolol succinate are preferred in patients with HFrEF
    • avoid abrupt cessation

  • beta blocker- noncardioselective
    • e.g. - Propranolol
    • avoid in patients with reactive airways disease
    • avoid abrupt cessation

  • alpha-1 blockers
    • e.g. - Doxazosin, Prazosin
    • these are associated with orthostatic hypotension, especially in older adults
    • they may be considered as second-line agent in patients with concomitant BPH

  • central alpha2-agonist and other centrally acting drugs
    • e.g. - Clonidine, Methyldopa
    • these are generally reserved as last-line because of significant CNS adverse effects, especially in older adults
    • avoid abrupt discontinuation of clonidine, which may induce hypertensive crisis; clonidine must be tapered to avoid rebound hypertension

  • direct vasodilators
    • e.g. - Hydralazine, Minoxidil
    • these are associated with sodium and water retention and reflex tachycardia; use with a diuretic and beta blocker
    • Hydralazine is associated with drug-induced lupus-like syndrome at higher doses
    • Minoxidil is associated with hirsutism and requires a loop diuretic. Minoxidil can induce pericardial effusion.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.